Australia Flu Vaccine Facility Will Be Unique in Southern Hemisphere

Influenza vaccine manufacturing facility

Seqirus will break ground early next year on a $600-million Melbourne vaccine facility.

PHOTO COURTESY SEQIRUS

Vaccine maker Seqirus announced plans to break ground early next year on a $600-million influenza vaccine manufacturing facility in Melbourne, Australia.

Capable of producing seasonal and pandemic flu vaccines, the plant will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere, says the company.

Built on a site near the city’s airport, the plant is expected to be operational in mid-2026. Plans for the facility followed an agreement with the Victoria government for onshore manufacturing to supply more than 10 years of influenza pandemic vaccines, anti-venoms and Q-Fever vaccine. The company recently completed a $140-million expansion of a facility in Holly Springs, N.C., that uses a similar technology platform.

Related Link: ENR 2020 Global Sourcebook PDF (subscription required)

Bruce Buckley is a freelance writer and photographer based in the Washington, D.C., area.

Post a comment to this article

Enhancing Collaboration and Surpassing Traditional Design-Build Methods with Progressive Design-Build

Earn: 1 PDH; 1 AIA LU/Elective; 0.1 IACET CEU

Progressive Design-Build is reshaping large infrastructure projects by addressing key issues with the traditional Design-Build approach. We'll explore how PDB fosters collaboration between owners, design-builders, and design teams to develop a well-defined scope and budget, plus minimizes cost overruns and reduces liability claims.